Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
This is the first comparative study in patients with metastatic melanoma refractory to PD-1/CTLA-4 inhibition and showed significantly longer outcomes in cases treated with pembrolizumab/lenvatinib versus CC.
Authors
- Panagiotis Diamantopoulos (ORCID: https://orcid.org/0000-0003-2692-5944)
- Michalis Liontos (ORCID: https://orcid.org/0000-0001-7192-4575)
- Dimitrios C. Ziogas (ORCID: https://orcid.org/0000-0003-2620-4004)
- Spyridon Bouros
- Amalia Anastasopoulou (ORCID: https://orcid.org/0000-0002-2147-7583)
- Aikaterini Gkoufa (ORCID: https://orcid.org/0000-0001-5644-8208)
- Helen J Gogas (ORCID: https://orcid.org/0000-0002-0451-2885)
- G. Lyrarakis
Institutions
- National and Kapodistrian University of Athens (GR)
- Alexandra Hospital (GR)
- Laiko General Hospital of Athens (GR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.3389/fonc.2024.1420879
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.41